PNT2004

**PNT2004** is a fibroblast activation protein-α (FAP-α)-targeted radioligand therapy program from POINT Biopharma, designed as a pan-cancer radiotheranostic agent. It employs a boronic acid-based FAP inhibitor conjugated to radioisotopes such as lutetium-177 (177Lu-PNT6555) for therapy and gallium-68 (68Ga-PNT6555) for imaging, with preclinical exploration of actinium-225 (225Ac-PNT2004). The lead candidate PNT6555 is in the FRONTIER phase 1 trial (NCT05432193), evaluating safety, tolerability, and dosimetry in FAP-avid solid tumors including colorectal cancer, pancreatic ductal adenocarcinoma, esophageal carcinoma, melanoma, and soft tissue sarcoma, with dosing starting at 4 GBq and escalation in 2-4 GBq increments every 6 weeks.[1][2][3][5]

Other names

PNT6555PNT-6555PNT 6555